Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Foot Rot D005535 1 associated lipids
Frostbite D005627 1 associated lipids
Strongyle Infections, Equine D013319 1 associated lipids
Basal Ganglia Hemorrhage D020145 1 associated lipids
Osteoblastoma D018215 1 associated lipids
Edema, Cardiac D004489 1 associated lipids
Radiculopathy D011843 1 associated lipids
Erythromelalgia D004916 1 associated lipids
Oligomenorrhea D009839 1 associated lipids
Intracranial Hemorrhage, Hypertensive D020299 1 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Wang JP et al. Antiplatelet effect of hsien-ho-t'sao (Agrimonia pilosa). 1985 Am. J. Chin. Med. pmid:3927704
Yan LG et al. Injectable caltrop fruit saponin protects against ischemia-reperfusion injury in rat brain. 2011 Am. J. Chin. Med. pmid:21476209
Takase B et al. Effects of bepridil on silent myocardial ischemia and eicosanoid metabolism in chronic stable angina pectoris after healing of myocardial infarction. 1994 Am. J. Cardiol. pmid:8198031
Fulton DR et al. Effects of current therapy of Kawasaki disease on eicosanoid metabolism. 1988 Am. J. Cardiol. pmid:2454025
Catella-Lawson F et al. Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease. 2001 Am. J. Cardiol. pmid:11472700
Hanet C et al. Myocardial protection by intracoronary nicardipine administration during percutaneous transluminal coronary angioplasty. 1987 Am. J. Cardiol. pmid:2953226
Faraday N et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. 2006 Am. J. Cardiol. pmid:16950183
Yasu T et al. Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. 1993 Am. J. Cardiol. pmid:8480641
Willerson JT et al. Potential usefulness of combined thromboxane A2 and serotonin receptor blockade for preventing the conversion from chronic to acute coronary artery disease syndromes. 1990 Am. J. Cardiol. pmid:2146868
McDaniel HG et al. Platelet function abnormalities in response to arachidonic acid in the acute phase of myocardial infarction. 1983 Am. J. Cardiol. pmid:6416046
De Caterina R et al. Inhibition of platelet function by injectable isosorbide dinitrate. 1984 Am. J. Cardiol. pmid:6428211
Eldar M et al. Bradykinin level in the great cardiac vein during balloon angioplasty of the left anterior descending coronary artery. 1992 Am. J. Cardiol. pmid:1466338
Dabaghi SF et al. Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. 1994 Am. J. Cardiol. pmid:7942533
Graziani F et al. Thromboxane production in morbidly obese subjects. 2011 Am. J. Cardiol. pmid:21439532
Théroux P et al. Hemodynamic, platelet and clinical responses to prostacyclin in unstable angina pectoris. 1990 Am. J. Cardiol. pmid:2109927
Feldman M and Cryer B Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. 1999 Am. J. Cardiol. pmid:10468077
Willerson JT et al. Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms. 1984 Am. J. Cardiol. pmid:6391133
Hirsh PD et al. Effects of provocation on transcardiac thromboxane in patients with coronary artery disease. 1983 Am. J. Cardiol. pmid:6829431
Walinsky P et al. Beneficial effects of ibuprofen in pacing-induced myocardial ischemia. 1983 Am. J. Cardiol. pmid:6829434
Milani M et al. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia. 1995 Am. J. Cardiol. pmid:7604798
Roy L et al. Increased plasma concentrations of prostacyclin metabolite 6-keto-PGF1 alpha in essential hypertension. Influence of therapy with labetalol. 1983 Am. J. Cardiol. pmid:6823861
Shen H et al. Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). 2009 Am. J. Cardiol. pmid:19660620
Lam JY et al. Platelet aggregation, coronary artery disease progression and future coronary events. 1994 Am. J. Cardiol. pmid:8109546
Timmermans C et al. Ridogrel in the setting of percutaneous transluminal coronary angioplasty. 1991 Am. J. Cardiol. pmid:1872272
Mason PJ et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. 2005 Am. J. Cardiol. pmid:16275179
Rehr RB et al. Mechanism of nitroglycerin-induced coronary dilatation: lack of relation to intracoronary thromboxane concentrations. 1984 Am. J. Cardiol. pmid:6437206
Montalescot G et al. Early thromboxane release during pacing-induced myocardial ischemia with angiographically normal coronary arteries. 1990 Am. Heart J. pmid:2248190
Hirsh PD et al. Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. 1982 Am. Heart J. pmid:7102506
Smith EF and Lefer AM Stabilization of cardiac lysosomal and cellular membranes in protection of ischemic myocardium due to coronary occlusion:efficacy of the nonsteroidal anti-inflammatory agent, naproxen. 1981 Am. Heart J. pmid:7211667
Nakashima Y et al. Sustained-release nifedipine (nifedipine-L) suppresses plasma thromboxane B2 and 6-keto prostaglandin F1 alpha in both young male smokers and nonsmokers. 1990 Am. Heart J. pmid:2353613
Ikonomidis I et al. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. 2005 Am. Heart J. pmid:15894964
Kishi Y et al. Inhibition of platelet aggregation by prostacyclin is attenuated after exercise in patients with angina pectoris. 1992 Am. Heart J. pmid:1736562
Tomoda H Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). 1986 Am. Heart J. pmid:3532743
Nitz RE and Martorana PA The activity of molsidomine in experimental models of ischemic cardiac disease. 1985 Am. Heart J. pmid:3919549
Buchanan MR et al. Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease. 1987 Am. Heart J. pmid:2953219
Walinsky P et al. Thromboxane A2 in acute myocardial infarction. 1984 Am. Heart J. pmid:6485997
Rubenstein MD et al. Platelet activation in clinical coronary artery disease and spasm. 1981 Am. Heart J. pmid:6455912
De Caterina R et al. Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: relationship between plasma drug concentration and hemodynamic effects. 1990 Am. Heart J. pmid:2321506
Lorenzoni R et al. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. 2004 Am. Heart J. pmid:15215815
Buerke M et al. Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. 1995 Am. Heart J. pmid:7661062
Mehta J et al. Thromboxane release in coronary artery disease: spontaneous versus pacing-induced angina. 1984 Am. Heart J. pmid:6695662
De Servi S et al. Coronary vasoconstrictor response to cold pressor test in variant angina: lack of relation to intracoronary thromboxane concentrations. 1987 Am. Heart J. pmid:3630891
Cotter G et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? 2004 Am. Heart J. pmid:14760328
Mehta J and Mehta P Prostacyclin and thromboxane A2 production by human cardiac atrial tissues. 1985 Am. Heart J. pmid:3880988
Friedrich T et al. Follow-up of prostaglandin plasma levels after acute myocardial infarction. 1985 Am. Heart J. pmid:3880994
O'Connor KM et al. The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models. 1989 Am. Heart J. pmid:2929400
Zhu BQ and Parmley WW Modification of experimental and clinical atherosclerosis by dietary fish oil. 1990 Am. Heart J. pmid:2105047
Neri Serneri GG et al. Abnormal cardiocoronary thromboxane A2 production in patients with unstable angina. 1985 Am. Heart J. pmid:3984828
O'Connor KM et al. Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion. 1986 Am. Heart J. pmid:3953390
Roy L et al. Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease. 1985 Am. Heart J. pmid:3158183
Austin JC et al. Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion. 1988 Am. Heart J. pmid:3344655
Yamada Y et al. Possible mechanism of vascular reocclusion after initially successful thrombolysis with recombinant tissue-type plasminogen activator. 1991 Am. Heart J. pmid:1903579
Arora RR et al. Laser-induced stimulation of thromboxane B2 synthesis in human blood platelets: role of superoxide radicals. 1993 Am. Heart J. pmid:8381256
FitzGerald GA et al. Cigarette smoking and hemostatic function. 1988 Am. Heart J. pmid:3276116
Jouve R et al. Thromboxane B2, 6-keto-PGF1 alpha, PGE2, PGF2 alpha, and PGA1 plasma levels in arteriosclerosis obliterans: relationship to clinical manifestations, risk factors, and arterial pathoanatomy. 1984 Am. Heart J. pmid:6581715
Rebuzzi AG et al. Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis. 1992 Am. Heart J. pmid:1539506
Cambria RA et al. Thromboxane synthetase inhibition decreases polymorphonuclear leukocyte activation following hindlimb ischemia. 1991 Am Surg pmid:1847027
Ingster LM and Feinleib M Salicylate intake and cardiovascular disease: Ingster and Feinleib respond to Hu and Willett. 1998 Am J Public Health pmid:9702172
Satterfield S et al. Biochemical markers of compliance in the Physicians' Health Study. 1990 Sep-Oct Am J Prev Med pmid:2268456
Natarajan G et al. Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants. 2008 Am J Perinatol pmid:18726836
Brown HL et al. Plasma and amniotic fluid prostacyclin and thromboxane in mild pregnancy-induced hypertension. 1987 Am J Perinatol pmid:3566883
Mehta P et al. Plasma concentrations of thromboxane and prostacyclin metabolites in patients with bone tumors. 1985 Am J Pediatr Hematol Oncol pmid:2994511
Jung TT and Juhn SK Prostaglandins in human cholesteatoma and granulation tissue. 1988 Am J Otol pmid:3177602
Leese PT et al. Valdecoxib does not impair platelet function. 2002 Am J Emerg Med pmid:12098171
Andersson T et al. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. 2012 Am J Cardiovasc Drugs pmid:22631032
Elissalde MH and Beier RC Stimulation and release of prostaglandins and thromboxane from macrophages by cotton dust associated lipopolysaccharides. 1990 Am Ind Hyg Assoc J pmid:2270833
Tanaka H et al. Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. 1999 Allergy pmid:10380781
Oosaki R et al. Urinary leukotriene E4 and 11-dehydrothromboxane B2 in patients with aspirin-sensitive asthma. 1997 Allergy pmid:9188934
Mita H et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. 2001 Allergy pmid:11703219
Collins CE et al. Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. 1996 Aliment. Pharmacol. Ther. pmid:8791957
Treiber G et al. The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa. 2006 Aliment. Pharmacol. Ther. pmid:16393293
Van Hecken A et al. Effects of enteric-coated, low-dose aspirin on parameters of platelet function. 2002 Aliment. Pharmacol. Ther. pmid:12197849
Cole AT et al. Low dose aspirin: selective inhibition of rectal dialysis thromboxane B2 in healthy volunteers. 1994 Aliment. Pharmacol. Ther. pmid:7865644
Carty E et al. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. 2000 Aliment. Pharmacol. Ther. pmid:10848666
Wannhoff A et al. Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt. 2016 Aliment. Pharmacol. Ther. pmid:26919285
Signore C et al. Markers of oxidative stress and systemic vasoconstriction in pregnant women drinking > or =48 g of alcohol per day. 2008 Alcohol. Clin. Exp. Res. pmid:18715278
Siler-Khodr TM et al. Effect of ethanol on thromboxane and prostacyclin production in the human placenta. 2000 Alcohol pmid:10963940
Hillbom M et al. Effects of ethanol on platelet function. 1985 May-Jun Alcohol pmid:4026960
Shalina RI et al. [Synthesis of prostaglandins and lipid peroxidation in pregnant women with gestosis]. 1988 Akush Ginekol (Mosk) pmid:3213902
Bashakin NF et al. [The functional characteristics of the prostacyclin-thromboxane system in newborn infants with a history of acute and chronic intrauterine hypoxia]. 1993 Akush Ginekol (Mosk) pmid:8311150
Fernández-Cruz E et al. Increased synthesis and production of prostaglandin E2 by monocytes from drug addicts with AIDS. 1989 AIDS pmid:2496725
Patrono C et al. Radioimmunoassay measurement of stable metabolites of platelet arachidonic acid: a convenient method for the in vitro and ex vivo evaluation of cyclo-oxygenase inhibitors. 1980 Agents Actions Suppl. pmid:6787852
Patrono C et al. Inhibition of platelet cyclooxygenase by aspirin-like drugs: methods for in vitro and ex vivo assessment. 1979 Agents Actions Suppl. pmid:115255
Chignard M et al. Arachidonate-mediated bronchoconstriction and platelet activation are inhibited by microgram doses of compound L8027 which are not selective for thromboxane synthetase. 1979 Agents Actions Suppl. pmid:291306
Peskar BA and Holland A Plasma levels of immunoreactive 15-keto-13,14-dihydro-thromboxane B2 in guinea pigs during anaphylaxis and after histamine injection. 1979 Agents Actions Suppl. pmid:294148
Cerletti C et al. Comparison of the effects of oral and intravenous aspirin administration on platelet and peripheral vascular cyclo-oxygenase activity: studies in rats and in man. 1986 Agents Actions Suppl. pmid:3101444
Mihai K et al. Association between total cholesterol and thromboxane B2 levels in offspring of parents suffering from premature coronary artery disease. 1992 Agents Actions Suppl. pmid:1632293
Petö J et al. Association between total cholesterol and plasma thromboxane B2 in human adults. 1992 Agents Actions Suppl. pmid:1632296
Mentz P and Giessler C Biosynthesis of TXB2 and 6-oxo-PGF1 alpha in the heart and other tissues under pathophysiological conditions. 1992 Agents Actions Suppl. pmid:1632315
Ahnfelt-Rønne I et al. Macrophages from adjuvent arthritic rats preferentially synthetize prostacyclin. 1980 Agents Actions pmid:6992544
Ghanem NS et al. The cardiac and renal effects of the complement fragment C5a des Arg are partly mediated by the release of histamine and arachidonic acid metabolites. 1989 Agents Actions pmid:2473617
De Clerck F et al. Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine. 1984 Agents Actions pmid:6543415
Srivastava R et al. Prostanoid mediated effects of centchroman, a non-steroidal oral contraceptive. 1986 Agents Actions pmid:3532722
Nosál R et al. Antihistaminic drug bromadryl and stimulated platelet aggregation. 1994 Agents Actions pmid:7976789
Conti P et al. Augmentation of thromboxane production in vitro by polymorphonuclears and macrophages exposed to IL1/LP. 1986 Agents Actions pmid:3485895
Hoult JR et al. Failure of anti-inflammatory steroids to inhibit prostaglandin release from the hydronephrotic rabbit kidney. 1986 Agents Actions pmid:3962772
Lesch ME et al. The effects of (R)-N-(1-methyl-2-phenylethyl) adenosine (L-PIA), a standard A1-selective adenosine agonist on rat acute models of inflammation and neutrophil function. 1991 Agents Actions pmid:1838897
Berti F et al. Immune release of histamine and other lipid mediators from guinea-pig isolated kidney: antagonism by BN-52021. 1990 Agents Actions pmid:1696776
Nosál R et al. Effect of chloroquine on isolated mast cells. 1991 Agents Actions pmid:1716835
Conti P et al. Effect of supernatants from PHA-stimulated and non-stimulated lymphocyte cultures on thromboxane B2 release by polymorphonuclear leukocytes in vitro. 1985 Agents Actions pmid:4003201